Elena A Tukhovskaya, Elvira R Shaykhutdinova, Irina A Pakhomova, Gulsara A Slashcheva, Natalya A Goryacheva, Elena S Sadovnikova, Ekaterina A Rasskazova, Vitaly A Kazakov, Igor A Dyachenko, Alina A Frolova, Alexey N Brovkin, Vasiliy E Kaluzhsky, Mikhail Yu Beburov, Arkady N Murashev
The aim of the study was to investigate the effect of AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) on the consequences of metabolic syndrome and type 2 diabetes induced by the consumption of a high-fat diet (HFD) in male C57Bl/6 mice. Additionally, the animals from group 6 were administered Methotrexate (MTX) at a dose of 1 mg/kg in parallel with AICAR, which slows down the metabolism of AICAR. The animals were recorded with signs of metabolic syndrome and type 2 diabetes mellitus by recording their body weights, glucose and insulin levels, and the calculating HOMA-IRs...
December 11, 2022: International Journal of Molecular Sciences